Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K. von Birgelen C, et al. Among authors: hautvast rw. Lancet. 2014 Feb 1;383(9915):413-23. doi: 10.1016/S0140-6736(13)62037-1. Epub 2013 Oct 31. Lancet. 2014. PMID: 24183564 Clinical Trial.
DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population.
Tandjung K, Basalus MW, Sen H, Jessurun GA, Danse PW, Stoel M, Linssen GC, Derks A, van Loenhout TT, Nienhuis MB, Hautvast RW, von Birgelen C. Tandjung K, et al. Among authors: hautvast rw. Am Heart J. 2012 Apr;163(4):557-62. doi: 10.1016/j.ahj.2012.02.001. Am Heart J. 2012. PMID: 22520520 Clinical Trial.
Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H, Lam MK, Löwik MM, Danse PW, Jessurun GA, van Houwelingen KG, Anthonio RL, Tjon Joe Gin RM, Hautvast RW, Louwerenburg JH, de Man FH, Stoel MG, van der Heijden LC, Linssen GC, IJzerman MJ, Tandjung K, Doggen CJ, von Birgelen C. Sen H, et al. Among authors: hautvast rw. JACC Cardiovasc Interv. 2015 Jun;8(7):889-99. doi: 10.1016/j.jcin.2015.01.033. Epub 2015 May 20. JACC Cardiovasc Interv. 2015. PMID: 26003019 Free article. Clinical Trial.
Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
van der Heijden LC, Kok MM, Lam MK, Danse PW, Schramm AR, Jessurun GA, Tjon Joe Gin RM, van Houwelingen KG, Hautvast RW, Linssen GC, Sen H, Löwik MM, IJzerman MJ, Doggen CJ, von Birgelen C. van der Heijden LC, et al. Among authors: hautvast rw. Clin Res Cardiol. 2016 Mar;105(3):206-15. doi: 10.1007/s00392-015-0907-3. Epub 2015 Sep 2. Clin Res Cardiol. 2016. PMID: 26329584 Free PMC article. Clinical Trial.
Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).
Huisman J, van der Heijden LC, Kok MM, Danse PW, Jessurun GA, Stoel MG, van Houwelingen KG, Löwik MM, Hautvast RW, IJzerman MJ, Doggen CJ, von Birgelen C. Huisman J, et al. Among authors: hautvast rw. Am Heart J. 2016 May;175:121-9. doi: 10.1016/j.ahj.2016.02.012. Epub 2016 Feb 26. Am Heart J. 2016. PMID: 27179731 Free article. Clinical Trial.
Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial.
van der Heijden LC, Kok MM, Löwik MM, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Hartmann M, Linssen GC, Doggen CJM, von Birgelen C. van der Heijden LC, et al. Among authors: hautvast rwm. EuroIntervention. 2017 Apr 20;12(17):2128-2131. doi: 10.4244/EIJ-D-16-00571. EuroIntervention. 2017. PMID: 27916746 Free article. Clinical Trial.
Three-Year Clinical Outcome of Patients with Coronary Disease and Increased Event Risk Treated with Newer-Generation Drug-Eluting Stents: From the Randomized DUTCH PEERS Trial.
van der Heijden LC, Kok MM, Löwik MM, Danse PW, Jessurun GAJ, Hartmann M, Stoel MG, van Houwelingen KG, Hautvast RWM, Linssen GC, Doggen CJM, von Birgelen C. van der Heijden LC, et al. Among authors: hautvast rwm. Cardiology. 2017;137(4):207-217. doi: 10.1159/000464320. Epub 2017 Apr 27. Cardiology. 2017. PMID: 28445871 Clinical Trial.
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C. Zocca P, et al. Among authors: hautvast rwm. JACC Cardiovasc Interv. 2018 Mar 12;11(5):462-469. doi: 10.1016/j.jcin.2017.11.031. JACC Cardiovasc Interv. 2018. PMID: 29519378 Free article. Clinical Trial.
40 results